Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-03T08:52:34.257Z Has data issue: false hasContentIssue false
  • English
  • Français

Head and neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: a case–control study

Published online by Cambridge University Press:  22 October 2008

V Asefi ,
Z Mojtahedi ,
B Khademi ,
S Naeimi  and
A Ghaderi
V Asefi
Affiliation:
Division of ENT, Namazee Hospital, Iran
Z Mojtahedi
Affiliation:
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Iran
B Khademi
Affiliation:
Division of ENT, Namazee Hospital, Iran
S Naeimi
Affiliation:
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Iran
A Ghaderi*
Affiliation:
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Iran
*
Address for correspondence: Dr Abbas Ghaderi, Professor of Immunology, Shiraz Institute for Cancer Research, PO Box 71345-3119, Shiraz, Iran. Fax: 0098 711 2304952 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To investigate the association of two functional single nucleotide polymorphisms in the promoter region of the interleukin-18 gene, at positions −607 and −137, with head and neck squamous cell carcinoma.

Design:

Genomic deoxyribonucleic acid was extracted, by the salting-out method, from peripheral blood leukocytes. Single nucleotide polymorphisms of the interleukin-18 gene at positions −607 (cytosine/adenine) and −137 (guanine/cytosine) were analysed by sequence-specific polymerase chain reaction.

Subjects:

One hundred and eleven patients (86 men and 25 women; mean age 56.7±13.7 years) and 212 regional controls (165 men and 47 women; mean age 53.3±12.2 years) were studied. Control subjects comprised healthy volunteers or cancer-free individuals presenting with otolaryngological disease. The diagnosis of squamous cell carcinoma was confirmed histopathologically. Various clinical parameters were collected at diagnosis, including tumour site, tumour size, lymph node involvement, distant metastasis and stage.

Results:

There was no significant association between the allele, genotype or haplotype frequencies of the two single nucleotide polymorphisms of the interleukin-18 promoter and the head and neck squamous cell carcinoma susceptibility or clinical parameters at diagnosis.

Conclusion:

Interleukin-18 polymorphisms at positions −607 and −137 did not confer susceptibility to head and neck squamous cell carcinoma in southern Iranian patients.

Keywords

Squamous Cell CarcinomaInterleukin-18PolymorphismHead and Neck Neoplasms
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 4 , April 2009 , pp. 444 - 448
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Vokes, EE, Weichselbaum, RR, Lippman, SM, Hong, WK. Head and neck cancer. New Engl J Med 1993;328:184–94CrossRefGoogle ScholarPubMed
2 Marur, S, Forastiere, AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83:489–501CrossRefGoogle ScholarPubMed
3 Lund, VJ, Howard, DJ. Head and neck cancer in the young: a prognostic conundrum. J Laryngol Otol 1990;104:544–8CrossRefGoogle Scholar
4 Hopkins, J, Cescon, DW, Tse, D, Bradbury, P, Xu, W, Ma, C et al. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 2008;17:490–9CrossRefGoogle ScholarPubMed
5 Vairaktaris, E, Yiannopoulos, A, Vylliotis, A, Yapijakis, C, Derka, S, Vassiliou, S et al. Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 2006;21:246–50CrossRefGoogle ScholarPubMed
6 Nakanishi, K, Yoshimoto, T, Tsutsui, H, Okamura, H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001;12:53–72CrossRefGoogle ScholarPubMed
7 Vidal-Vanaclocha, F, Mendoza, L, Telleria, N, Salado, C, Valcárcel, M, Gallot, N et al. Clinical and experimental approaches to the pathophysiology of interleukin–18 in cancer progression. Cancer Metastasis Rev 2006;25:417–34CrossRefGoogle Scholar
8 Giedraitis, V, He, B, Huang, WX, Hillert, J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146–52CrossRefGoogle ScholarPubMed
9 Mojtahedi, Z, Naeimi, S, Farjadian, S, Omrani, GR, Ghaderi, A. Association of IL-18 promoter polymorphisms with predisposition to type 1 diabetes. Diabet Med 2006;23:235–9CrossRefGoogle ScholarPubMed
10 Bouzgarrou, N, Hassen, E, Schvoerer, E, Stoll-Keller, F, Bahri, O, Gabbouj, S et al. Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol 2008;80:607–14CrossRefGoogle ScholarPubMed
11 Bushley, AW, Ferrell, R, McDuffie, K, Terada, KY, Carney, ME, Thompson, PJ et al. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 2004;95:672–9CrossRefGoogle ScholarPubMed
12 Liu, Y, Lin, N, Huang, L, Xu, Q, Pang, G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 2007;26:613–18CrossRefGoogle ScholarPubMed
13 Miller, SA, Dykes, DD, Polesky, HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215CrossRefGoogle ScholarPubMed
14 Vairaktaris, E, Serefoglou, ZC, Yapijakis, C, Agapi, C, Vassiliou, S, Nkenke, E et al. The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res 2007;27:4011–14Google Scholar
15 Khademi, B, Razmkhah, M, Erfani, N, Gharagozloo, M, Ghaderi, A. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res 2008;14:45–50Google Scholar
16 Günel, N, Coşkun, U, Sancak, B, Günel, U, Hasdemir, O, Bozkurt, S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 2002;95:663–7CrossRefGoogle ScholarPubMed
17 Jebreel, A, Mistry, D, Loke, D, Dunn, G, Hough, V, Oliver, K et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007;121:246–52CrossRefGoogle Scholar
18 Wein, RO, Chandra, RK, Weber, RS. Disorders of head and neck. In: Brunicardi, FC, Andersen, DK, Billiar, TR, Dunn, DL, Hunter, JG, Pollock, RE. Schwartz's Principles of Surgery, 8th edn. New York: McGraw-Hill, 2005;515–16Google Scholar
19 Harling-Berg, CJ, Park, TJ, Knopf, PM. Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol 1999;101:111–27CrossRefGoogle ScholarPubMed